San Francisco— Researchers claim that an experimental anticlotting drug that failed to demonstrate benefit in 2 previous studies showed positive results in a new study. They said the experimental drug, cangrelor, may offer another option for reducing periprocedural complications from percutaneous coronary intervention (PCI). But others are not so sure.
Current guidelines recommend that patients being considered for PCI receive dual antiplatelet therapy (aspirin and a platelet adenosine diphosphate–receptor antagonist, usually clopidogrel) to reduce the risk of developing stent thrombosis or myocardial infarction. But to achieve maximum benefit, clopidogrel, an oral agent, should be given 6 to 12 hours before PCI, and its antiplatelet effect can remain for days.
Mitka M. Study Ignites Debate on New Anticoagulant. JAMA. 2013;309(17):1763–1764. doi:10.1001/jama.2013.3857
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: